Difference between revisions of "Kaposi sarcoma - null regimens"
Jump to navigation
Jump to search
m (Text replacement - "style="background-color:#1a9851" |Phase III" to "style="background-color:#1a9851" |Phase 3") |
m (→Regimen) |
||
| Line 20: | Line 20: | ||
|1998-2001 | |1998-2001 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
| − | |IM862 | + | |[[#IM862_monotherapy_77|IM862]] |
| style="background-color:#91cf60" |Seems to have superior TTP | | style="background-color:#91cf60" |Seems to have superior TTP | ||
|- | |- | ||
|} | |} | ||
''No active antineoplastic treatment.'' | ''No active antineoplastic treatment.'' | ||
| + | |||
===References=== | ===References=== | ||
Revision as of 12:21, 20 March 2022
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main KS page for current regimens.
All lines of therapy
Placebo
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Noy et al. 2005 (AMC 013) | 1998-2001 | Phase 3 (C) | IM862 | Seems to have superior TTP |
No active antineoplastic treatment.
References
- AMC 013: Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P; AIDS Malignancy Consortium. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. link to original article PubMed